---
title: "Chandra Bhagat Pharma Ltd (542934) — Share Price, Financials & Analysis"
symbol: "542934"
company: "Chandra Bhagat Pharma Ltd"
canonical: "https://tapetide.com/stocks/542934"
isin: "INE07QQ01016"
nse_symbol: "CHANDRABHAGATPHARMALTD"
bse_code: "542934"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 33.7
generated_at: "2026-09-13T18:52:19.554Z"
---

# Chandra Bhagat Pharma Ltd (542934)

Canonical page: https://tapetide.com/stocks/542934

## Company

- **NSE Symbol:** CHANDRABHAGATPHARMALTD
- **BSE Code:** 542934
- **ISIN:** INE07QQ01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2020-02-14
- **CEO:** Mr. Hemant Chandravadan Bhagat
- **Employees:** 40
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** cbcpharma.com

## About

Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures chemical and pharmaceutical products.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:50:38.038443Z.

- **Market Cap:** ₹33.7 Cr
- **Classification:** SME
- **P/E (reported):** 11.1
- **EPS (reported):** ₹2.03
- **Book Value:** ₹43.9
- **Price to Book:** 1.02
- **Dividend Yield:** 0%
- **ROE:** 9.2%
- **ROCE:** 17.1%
- **Debt to Equity:** 0.5
- **Revenue (yearly):** ₹119.6 Cr
- **Net Income:** ₹3 Cr
- **EBITDA:** ₹7.2 Cr
- **52-Week High:** ₹52.71
- **52-Week Low:** ₹29.7
- **RSI (14):** 17.65

## Key Insights

### Strengths

- Company has reduced debt.
- Stock is trading at 1.02 times its book value
- Promoter holding has increased by 0.83% over last quarter.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 5.92% over last 3 years.
- Earnings include an other income of Rs.3.35 Cr.
- Company has high debtors of 171 days.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 261.82% | 49.51% | -25.48% |
| ebitda margin growth | 36.51% | 227.17% | 33.48% |
| net income growth | 233.33% | 50% | 74% |
| revenue growth | 29.72% | -1% | 10% |
| roce | 77.39% | 44.06% | 12.15% |
| roe | 221.68% | 5.78% | 207.69% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 22 | 48 | 43 | 51 | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Expenses | 21 | 47 | 42 | 50 | 43 | 74 | 124 | 104 | 66 | 22 | 24 | 89 |
| Operating Profit | 2 | 2 | 2 | 1 | 1 | 2 | -5 | -2 | -1 | 0 | 2 | 2 |
| OPM % | 7 | 3.4 | 3.8 | 2.1 | 2.3 | 2.4 | -4.2 | -2 | -1.8 | -1.2 | 7 | 2.4 |
| Other Income | 0 | 0 | 0 | 1 | 1 | 0 | 7 | 4 | 3 | 2 | 0 | 3 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Tax % | 25 | 33 | 24 | 31 | 31 | 15 | 32 | 34 | -11 | 69 | 22 | 26 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.9 | 0.23 | 0.6 | 3.45 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 89 | 116 |
| Expenses | 85 | 92 | 102 | 91 | 67 | 91 | 116 | 228 | 88 | 112 |
| Operating Profit | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | 1 | 4 |
| OPM % | 4.9 | 4.7 | 4.3 | 3.3 | 5 | 3 | 2.8 | -3.2 | 0.7 | 3.3 |
| Other Income | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 11 | 3 | 3 |
| Interest | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 4 |
| Tax % | 27 | 33 | 22 | 26 | 32 | 27 | 22 | 33 | 26 | 26 |
| Net Profit | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 |
| EPS in Rs | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| Borrowings | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 |
| Other Liabilities | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 51 | 45 |
| Total Liabilities | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| Fixed Assets | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 99 | 90 |
| Total Assets | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 |
| Cash from Investing Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 |
| Cash from Financing Activity | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 2 | 3 | 1 | -1 | -4 | 2 |
| Free Cash Flow | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 4 | -6 | 8 |
| CFO/OP | -200 | -129 | 98 | -238 | 229 | 440 | 164 | -94 | -805 | 250 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 148 | 171 |
| Inventory Days | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days Payable | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash Conversion Cycle | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working Capital Days | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
| ROCE % | 15 | 17 | 13 | 7 | 7 | 9 | 7 | 8 | 6 | 12 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 71.8% | 71.8% | 70.11% | 69.09% | 68.24% | 68.69% | 68.77% | 69.29% | 71.2% | 72.19% | 73.02% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 1.33% | 1.33% | 0.48% | 0.61% | 0.61% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0.89% | 0.89% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 18.85% | 15.24% | 17.79% | 18.97% | 18.98% | 17.07% | 16.92% | 12.84% | 11.16% | 11.84% | 11.33% |
| Others | 9.36% | 12.96% | 12.1% | 11.94% | 12.78% | 12.02% | 12.09% | 17.39% | 17.03% | 15.36% | 15.65% |
| No. of Shareholders | 106 | 90 | 126 | 126 | 146 | 134 | 152 | 315 | 316 | 301 | 280 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 5 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 48.09 | Sell |
| EMA (10) | 46.11 | Sell |
| SMA (20) | 42.49 | Buy |
| EMA (20) | 44.03 | Buy |
| SMA (50) | 40.36 | Buy |
| EMA (50) | 41.37 | Buy |
| SMA (100) | 39.47 | Buy |
| EMA (100) | 42.21 | Buy |
| SMA (200) | 47.68 | Sell |
| EMA (200) | 50.09 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 54.97 | Neutral |
| MACD (12,26,9) | 2.58 | Buy |
| Stochastic (14,3,3) | 55.78 | Neutral |
| ADX (14) | 31.6 | Buy |
| Williams %R (14) | -50.69 | Neutral |
| ATR (14) | 1.89 | High Volatility |
| ROC (12) | 14.33 | Buy |
| Stoch RSI (14) | 9.38 | Buy |
| UO (7,14,28) | 48.16 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d510c333-4f73-40f3-b141-e5a0d3fc8e10.pdf) |
| 2026-09-01 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=354b2411-21a7-4f03-96ce-ee1a23d59aec.pdf) |
| 2026-08-20 | [Corrigendum Of AGM Notice](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=767c3333-a2f0-4bde-9ec8-31ab300abb9d.pdf) |
| 2026-08-06 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2b931dd1-fac2-4c04-9d8a-56ae5e219940.pdf) |
| 2026-08-06 | [Notice Of Shareholders Meeting Scheduled On 1St September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52e6f8eb-4673-454e-8acc-4bcefcfabc0e.pdf) |
| 2026-08-05 | [Board Meeting Outcome for For Approval Of Preferential Issue And Other Agenda](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e81da4b-6100-4088-9300-8bcbafec1959.pdf) |
| 2026-07-30 | [Board Meeting Intimation for Fund Raising Through Preferential Issue.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee4f7059-ad16-40a6-b25a-6fd936b40c07.pdf) |
| 2026-07-21 | [Non-Applicability Of CG Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe3b91e4-043d-4ef9-ba34-604bcca1e6b5.pdf) |
| 2026-05-25 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th May 2026 For Approval Of Audited Result As On 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e71768e4-108b-4bd0-bffc-26a7e5c23e84.pdf) |
| 2026-05-18 | [Board Meeting Intimation for Approval Of Audited Financial Results As On 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=591fd956-b52a-4091-b380-c55d111e9ee2.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-25 | [Financial Result For Period Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a09363e0-cfcc-4430-87b0-577e576ea087.pdf) |
| 2025-11-13 | [Un-Audited Result For Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b16bd352-0d09-4530-9fa7-2c80da2594da.pdf) |
| 2025-05-29 | [Result For The Financial Year March 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a637cf5d-82db-4652-8c62-16cbd3e7a0d4.pdf) |
| 2024-11-13 | [Result For The Half Year Ended As On September 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4eea7fe-1816-4562-8726-e1d3976fdf4f.pdf) |
| 2024-05-30 | [Result As On March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c95751e-a46b-4847-ae50-63471ff47be1.pdf) |
| 2023-11-09 | [Financial Result As On 30.09.2023.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9dacf24d-0fed-4a6a-ad1d-d9f77dbb7f3d.pdf) |
| 2023-05-22 | [Audited Financial Result Of The Company For The Period Ended 31St March, 2023.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19c08743-f650-442b-bd8e-c1c0257ce360.pdf) |
| 2022-11-14 | [Approval Of Un-Audited Financial Result As On 30Th September, 2022.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6eb8f0fc-5128-4c8e-bca6-6c81fa7b7d0b.pdf) |
| 2022-05-26 | [Board Meeting Outcome for Outcome Of The Board Meeting For Approval Of Audited Financial Result As On 31.03.2022.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9c66aa4-a9d2-4713-9124-a82f21480603.pdf) |
| 2022-05-26 | [Outcome Of The Board Meeting For Approval Of Audited Financial Result As On 31.03.2022.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c9d350d-b80e-48fd-a111-43c7827bb55c.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 Nov 2025 - Board meeting on 13 Nov 2025 to consider H1 FY ended 30 Sep 2025 unaudited financials. | [Board Meeting Intimation for For Approval Of Un-Audited Result For The Half Year Ended 30Th September 2025 7 Nov 2025 - Board meeting on 13 Nov 2025 to consider H1 FY ended 30 Sep 2025 unaudited financials.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a9fbf244-74f3-4015-a5a3-50bd52fba320.pdf) |
| 21 Jan - Exempt from corporate governance per Reg.15; no CG report required for quarter ended 31 Dec 2025. | [Non Applicability Of Corporate Governance Report Certificate. 21 Jan - Exempt from corporate governance per Reg.15; no CG report required for quarter ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f90e9e1-c34a-48ea-979f-a382c7b123b4.pdf) |
| 21 Apr - Company states corporate governance provisions and Q4 FY2026 report are not applicable under Regulation 15. | [Certificate For NON-Applicability Of Corporate Governance As On 31 March 2026. 21 Apr - Company states corporate governance provisions and Q4 FY2026 report are not applicable under Regulation 15.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70a9a4c9-7fc8-477d-8f84-f1493ac1328b.pdf) |
| 20 Oct 2025 - Chandra Bhagat Pharma exempt under SEBI Reg 15; no corporate governance report for quarter ended 30 Sep 2025. | [Disclosure 20 Oct 2025 - Chandra Bhagat Pharma exempt under SEBI Reg 15; no corporate governance report for quarter ended 30 Sep 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/88396613-8c82-4511-9ceb-0bcdbfad1d9b.pdf) |
| 13 Nov 2025 - Approved unaudited results for half-year ended 30 Sep 2025; limited review report dated 13 Nov 2025. | [Un-Audited Result For Half Year Ended September 30, 2025. 13 Nov 2025 - Approved unaudited results for half-year ended 30 Sep 2025; limited review report dated 13 Nov 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b16bd352-0d09-4530-9fa7-2c80da2594da.pdf) |
| 13 Nov 2025 - Approved unaudited half-year results for period ended 30 Sep 2025; limited review report dated 13 Nov 2025. | [Board Meeting Outcome for Outcome Of The Board Meeting Held On 13Th November 2025 For Approval Of Un-Audited Result As On 30.09.2025 13 Nov 2025 - Approved unaudited half-year results for period ended 30 Sep 2025; limited review report dated 13 Nov 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/60d3abc0-5add-44cb-85a1-e1dc57ae840c.pdf) |
| 12h - Company states corporate governance provisions and Q4 FY2026 report are not applicable under Regulation 15. | [Certificate For NON-Applicability Of Corporate Governance As On 31 March 2026. 12h - Company states corporate governance provisions and Q4 FY2026 report are not applicable under Regulation 15.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/70a9a4c9-7fc8-477d-8f84-f1493ac1328b.pdf) |
| 1 Apr - Opened Dubai international representative office; Certificate of Formation dated 31-Mar-2026. | [Disclosure Under Regulation 30. 1 Apr - Opened Dubai international representative office; Certificate of Formation dated 31-Mar-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f5411224-85f8-4636-bfda-25e902829c6f.pdf) |
| — | [Closure of Trading Window 31 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/570cca01-d4a0-4cef-a7f3-2aa506476798.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_3186_PSL_2012_2013_27022014180002.zip) |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b931dd1-fac2-4c04-9d8a-56ae5e219940.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/461c0b0c-2642-483a-9df8-5e2e00cd6e8e.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8a6daeba-8a5e-4850-a7be-53c25ab60007.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3d4be613-5374-4209-a087-576cbae36e94.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/542934/76304542934.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/542934/72656542934.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/542934/67726542934.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport//68081526801.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport//5268010319.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:52:19.554Z.